查看購物車
  • Simplified Chinese
  • English
2021-2031年歐洲治療性疫苗市場報告：範圍、細分、動態和競爭分析
市場調查報告書
商品編碼
1871434

2021-2031年歐洲治療性疫苗市場報告：範圍、細分、動態和競爭分析

Europe Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 133 Pages | 訂單完成後即時交付

價格

歐洲治療性疫苗市場預計將大幅成長，到 2031 年將達到約 147.6 億美元，高於 2024 年的 63.9 億美元，2024 年至 2031 年的年複合成長率(CAGR) 為 12.7%。

執行摘要和市場分析

歐洲治療性疫苗市場分為多個區域，包括德國、英國、法國、義大利、西班牙和歐洲其他地區。該市場的成長主要得益於先進的醫療保健體系和研發投入的增加。歐洲擁有許多領先的製藥和生物技術公司，致力於開發各種疾病（尤其是癌症）的創新疫苗療法。慢性病發病率的上升以及人們對個人化醫療日益成長的興趣，進一步推動了該地區對治療性疫苗的需求。預計在免疫療法的進步和新型疫苗技術的湧現的推動下，該市場將繼續保持上升勢頭，這些進步和技術為市場成長帶來了巨大的機會。

市場區隔分析

治療性疫苗市場可依產品類型、技術和最終用戶進行細分：

  • 按產品分類：市場包括癌症疫苗、傳染病疫苗等，其中癌症疫苗在 2024 年將佔據最大的市場佔有率。
  • 按技術分類：市場分為同種異體疫苗和自體疫苗，到 2024 年，同種異體疫苗將佔據市場佔有率的領先地位。
  • 按最終用戶分類：最終用戶主要是醫院、診所和其他機構，其中醫院在 2024 年將佔最大佔有率。

市場展望

治療性疫苗旨在刺激免疫系統，以治療癌症、自體免疫疾病和慢性感染等疾病。疫苗研發投入的不斷增加對於治療性疫苗市場的成長至關重要，它能夠促進創新並加速慢性病新療法的研發。過去十年，全球疫苗研發資金大幅成長，各國政府、私人機構和製藥公司都意識到治療性疫苗在滿足未被滿足的醫療需求方面發揮關鍵作用。例如，葛蘭素史克（GSK）在2021年投入64.6億美元用於研發，重點在於包含43種藥物和21種疫苗的研發管線，其中相當一部分針對傳染病。

此外，腫瘤疫苗領域呈現顯著的研發趨勢，許多公司正利用mRNA技術開發針對多種癌症的治療性疫苗。例如，eTheRNA Immunotherapies公司獲得了歐盟委員會690萬歐元的資助，用於開發一種創新的mRNA癌症疫苗，以治療復發性或轉移性HPV16陽性癌症。同樣，貝爾法斯特女王大學的研究人員也獲得了資助，探索三陰性乳癌的新療法，重點是開發一種mRNA疫苗，以增強免疫系統靶向攜帶p53突變的癌細胞的能力。這類資助計畫正在推動治療性疫苗的創新，為包括癌症和慢性感染在內的多種疾病帶來更有效的治療方法。

國家概況

歐洲治療性疫苗市場涵蓋德國、義大利、法國、英國、西班牙等主要國家，其中德國在2024年佔據最大的市場佔有率。德國擁有全球最先進的醫療保健體系之一，其強大的製藥和生物技術產業為治療性疫苗的研發和商業化提供了有力支持。德國擁有龐大的患者群體，對高品質醫療保健服務的需求旺盛。慢性病和傳染病（例如B型肝炎）的日益普及進一步推動了德國市場的發展。例如，2022年德國報告了16,674例乙型肝炎病例。

德國強大的科學研究生態系統，以學術機構、醫院和生技公司之間的合作為特徵，正在加速新型治療性疫苗的研發。德國癌症研究中心（DKFZ）處於癌症免疫療法研究的前沿，為德國的創新格局做出了重大貢獻。 2024年8月，DKFZ的研究人員推出了一種旨在提高HPV疫苗接種率的新型疫苗，該疫苗已被證實能夠有效預防多種致癌型HPV病毒感染。

公司簡介

治療性疫苗市場的主要參與者包括CureVac SE、THERAVECTYS SA、Transgene SA、INOVIO Pharmaceuticals Inc、ISA Pharmaceuticals BV、Amgen Inc、Merck & Co Inc、印度血清研究所、BioNTech SE和Dendreon。這些公司正採取多種策略，包括擴張、產品創新以及併購，以增強其市場佔有率並為消費者提供創新產品。

目錄

第1章：引言

第2章：執行概要

  • 關鍵見解

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基礎數字：
    • 數據三角測量：
    • 國家層面資料：

第4章：歐洲治療性疫苗市場－主要市場動態

  • 市場促進因素
    • 慢性病盛行率上升
    • 增加疫苗研發的投資與資金投入
  • 市場限制
    • 監管挑戰
  • 市場機遇
    • 拓展產品線
  • 未來趨勢
    • 疫苗技術的進步
  • 駕駛員和安全帶的影響：

第5章：治療性疫苗市場－歐洲市場分析

  • 2021-2031年歐洲治療性疫苗市場收入
  • 歐洲治療性疫苗市場預測分析

第6章：歐洲治療性疫苗市場分析－依產品分類

  • 癌症疫苗
  • 傳染病疫苗
  • 其他

第7章：歐洲治療性疫苗市場分析－依技術分類

  • 同種異體疫苗
  • 自體疫苗

第8章：歐洲治療性疫苗市場分析－以最終用戶分類

  • 醫院
  • 診所
  • 其他

第9章：歐洲治療性疫苗市場—國別分析

  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區

第10章：治療性疫苗市場－產業概況

  • 概述
  • 治療性疫苗市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第11章：公司簡介

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第12章：附錄

Product Code: BMIRE00032091

The Europe therapeutic vaccines market is projected to grow significantly, reaching approximately US$ 14.76 billion by 2031, up from US$ 6.39 billion in 2024, with a compound annual growth rate (CAGR) of 12.7% during the period from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccines market in Europe is divided into several regions, including Germany, the UK, France, Italy, Spain, and the Rest of Europe. The growth of this market is driven by advanced healthcare systems and increased investments in research and development. Europe hosts numerous leading pharmaceutical and biotechnology companies that are dedicated to developing innovative vaccine therapies for various diseases, particularly cancer. The rising incidence of chronic diseases and the growing interest in personalized medicine are further propelling the demand for therapeutic vaccines in the region. The market is expected to continue its upward trajectory, bolstered by advancements in immunotherapy and the emergence of new vaccine technologies that present significant opportunities for growth.

Market Segmentation Analysis

The therapeutic vaccines market can be segmented based on product type, technology, and end user:

  • By Product: The market includes cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
  • By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
  • By End User: The end users are primarily hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

Therapeutic vaccines are designed to stimulate the immune system to treat conditions such as cancer, autoimmune diseases, and chronic infections. The increasing investments in vaccine development are crucial for the growth of the therapeutic vaccines market, fostering innovation and accelerating the creation of new treatments for chronic diseases. Over the last decade, global funding for vaccine R&D has surged, with governments, private entities, and pharmaceutical companies acknowledging the critical role of therapeutic vaccines in meeting unmet medical needs. For example, GlaxoSmithKline (GSK) allocated US$ 6.46 billion towards R&D in 2021, focusing on a pipeline that includes 43 medicines and 21 vaccines, with a significant portion targeting infectious diseases.

Moreover, there is a notable trend towards oncology-focused vaccines, with companies leveraging mRNA technology to develop therapeutic vaccines for various cancers. For instance, eTheRNA Immunotherapies received a €6.9 million grant from the European Commission to develop an innovative mRNA cancer vaccine for treating recurrent or metastatic HPV16+ cancers. Similarly, researchers at Queen's University Belfast secured funding to explore new treatments for triple-negative breast cancer, focusing on developing an mRNA vaccine that enhances the immune system's ability to target cancer cells with p53 mutations. Such funding initiatives are driving innovations in therapeutic vaccines, leading to more effective treatments for a range of diseases, including cancers and chronic infections.

Country Insights

The therapeutic vaccines market in Europe includes key countries such as Germany, Italy, France, the UK, Spain, and others, with Germany holding the largest market share in 2024. Germany boasts one of the most advanced healthcare systems globally, supported by a robust pharmaceutical and biotechnology sector that facilitates the development and commercialization of therapeutic vaccines. The country has a large patient population and a high demand for quality healthcare services. The increasing prevalence of chronic and infectious diseases, such as hepatitis B, further drives the market in Germany. For instance, in 2022, Germany reported 16,674 cases of hepatitis B.

Germany's strong research ecosystem, characterized by collaboration among academic institutions, hospitals, and biotech firms, is accelerating the development of new therapeutic vaccines. The German Cancer Research Center (DKFZ) is at the forefront of cancer immunotherapy research, contributing significantly to the country's innovation landscape. In August 2024, DKFZ researchers introduced a novel vaccine aimed at increasing HPV vaccination rates, demonstrating efficacy in protecting against various cancer-causing HPV types.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative products to consumers.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Europe Therapeutic Vaccines Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic Conditions
    • 4.1.2 Increasing Investments and Funding for Vaccine Development
  • 4.2 Market Restraints
    • 4.2.1 Regulatory Challenges
  • 4.3 Market Opportunities
    • 4.3.1 Extending Product Pipeline
  • 4.4 Future Trends
    • 4.4.1 Advancements in Vaccine Technology
  • 4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - Europe Market Analysis

  • 5.1 Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 5.2 Europe Therapeutic Vaccines Market Forecast Analysis

6. Europe Therapeutic Vaccines Market Analysis - by Product

  • 6.1 Cancer Vaccine
    • 6.1.1 Overview
    • 6.1.2 Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.2 infectious Disease Vaccine
    • 6.2.1 Overview
    • 6.2.2 infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.3 Others
    • 6.3.1 Overview
    • 6.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. Europe Therapeutic Vaccines Market Analysis - by Technology

  • 7.1 Allogenic Vaccine
    • 7.1.1 Overview
    • 7.1.2 Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 7.2 Autologous Vaccine
    • 7.2.1 Overview
    • 7.2.2 Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Europe Therapeutic Vaccines Market Analysis - by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.2 Clinics
    • 8.2.1 Overview
    • 8.2.2 Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Europe Therapeutic Vaccines Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.2.1 Germany: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.2.2 Germany: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.2.3 Germany: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.3 United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.3.1 United Kingdom: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.3.2 United Kingdom: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.3.3 United Kingdom: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.4 France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.4.1 France: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.4.2 France: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.4.3 France: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.5 Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.5.1 Italy: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.5.2 Italy: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.5.3 Italy: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.6 Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.6.1 Spain: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.6.2 Spain: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.6.3 Spain: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.7 Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.7.1 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.7.2 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.7.3 Rest of Europe: Europe Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Therapeutic Vaccines Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Dendreon
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 BioNTech SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Serum Institute of India Pvt. Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Merck & Co Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Amgen Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 ISA Pharmaceuticals BV
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 INOVIO Pharmaceuticals Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Transgene SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 THERAVECTYS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 CureVac SE
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Therapeutic Vaccines Market Segmentation
  • Table 2. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Table 3. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
  • Table 4. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
  • Table 5. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
  • Table 6. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
  • Table 7. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 8. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 9. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 10. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 11. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 12. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 13. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 14. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 15. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 16. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 17. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 18. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 19. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 20. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 21. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 22. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 23. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 24. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 25. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 26. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 27. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. Europe Therapeutic Vaccines Market Segmentation - Country
  • Figure 2. Europe Therapeutic Vaccines Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Europe Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 6. Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 7. infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 8. Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 9. Europe Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 10. Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 11. Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 12. Europe Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 13. Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 14. Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 15. Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 16. Europe Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 17. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 18. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 19. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 20. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 21. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 22. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 23. Growth Strategies in the Therapeutic Vaccines Market